Data preprocessing and quality control This study employed the FDA-recommended data extraction protocol to retrieve all case reports associated with GLP-1 receptor agonist and metformin combination therapy from the first quarter of 2004 (2004 Q1) to the third quarter of 2024 (2024 Q3)
Growth hormone reaches pinnacle levels during puberty but declines with age, decreasing 14% per decade after age 35
Thus, differences in genotype may represent only part of a complex interaction between host and virus
The metabolic benefits of GLP-1 therapy extend well beyond weight loss, including beta-cell preservation, improved insulin sensitivity, and cardiovascular risk reduction
The multifaceted role of mitochondria in ASD is schematically presented in Fig
GLP-1 medications are also being studied for benefits beyond weight loss, including improved heart and kidney health and possible effects on addiction-related behaviors